Connect Biopharma Holdings (CNTB) Change in Accured Expenses (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted Change in Accured Expenses of -$404000.0 for Q1 2026, down 118.13% sequentially from $2.2 million in Q4 2025, and up 28.37% YoY from -$314718.2 in Q1 2025.
Connect Biopharma Holdings (CNTB) Change in Accured Expenses (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Change in Accured Expenses for 3 years, with the latest figure at -$404000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 28.37% year-over-year to -$404000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 218.61% YoY) and the FY2025 annual result came in at $3.4 million, up 300.24% from the prior year.
- Change in Accured Expenses declined to -$404000.0 in Q1 2026 per CNTB's latest filing, from $2.2 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $2.2 million in Q4 2025 and troughed at -$1.3 million in Q2 2024.
- A 3-year average of $141888.9 and a median of -$82000.0 in 2024 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 1318.29% in 2025, down 177.79% in 2025.
- Over 3 years, Change in Accured Expenses stood at -$1.0 million in 2024, then jumped by 319.29% to $2.2 million in 2025, then tumbled by 118.13% to -$404000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$404000.0, $2.2 million, and $999000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Connect Biopharma Holdings | 148.41 Mn | 148.41 Mn | - | 3.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.06 Mn |
| Jun 30, 2026 | 3.06 Mn |
| Mar 31, 2026 | -404,000.00 |
| Mar 31, 2026 | -404,000.00 |
| Dec 31, 2025 | 2.23 Mn |
| Dec 31, 2025 | 2.23 Mn |
| Sep 30, 2025 | 999,000.00 |
| Sep 30, 2025 | 999,000.00 |
| Jun 30, 2025 | 695,000.00 |
| Jun 30, 2025 | 695,000.00 |
| Mar 31, 2025 | -564,000.00 |
| Mar 31, 2025 | -564,000.00 |
| Dec 31, 2024 | -1.02 Mn |
| Dec 31, 2024 | -1.02 Mn |
| Sep 30, 2024 | -82,000.00 |
| Sep 30, 2024 | -82,000.00 |
| Jun 30, 2024 | -1.30 Mn |
| Jun 30, 2024 | -1.30 Mn |
| Mar 31, 2024 | 725,000.00 |
| Mar 31, 2024 | 725,000.00 |